Clinical guidelines for the treatment of depressive disorders. IV. Pharmacotheraphy and other biological treatments;Lignes directrices cliniques du traitement des troubles dépressifs. IV. Pharmacothérapie et autres traitements biologiques

Canadian Journal of Psychiatry

Volumn 46, Issue SUPPL., 2001, Pages

  Kennedy, Sidney H ^a   Lam, Raymond W ^a   Cohen, Nicole L ^a   Ravindran, Arun V ^a   Enns, Murray W ^a   Kutcher, Stanley P ^a   Parikh, Sagar V ^a   Reesal, Robin T ^a   Segal, Zindel V ^a   Thorpe, Lilian ^a   Vincent, Pierre ^a   Whitney, Diane K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROTOXICITY; PHOTOTHERAPY; PRACTICE GUIDELINE; PSYCHOSURGERY; PSYCHOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 19244384281     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
2. Treating depression to remission
3. The increasing use of polypharmacotherapy for refractory mood disorders: 22 Years of study
4. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
5. Antidepressant treatment of depression: A metaanalysis
6. Efficacy of new generation antidepressants: Metaanalysis of imipramine-controlled studies
7. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
8. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis
9. Atypical antidepressants versus imipramine in the treatment of major depression: A meta-analysis
10. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
11. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
12. Paroxetine: A selective reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study
13. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study
14. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
15. Paroxetine in the treatment of melancholia and severe depression
16. Efficacy of moclobemide in different patient groups: A metaanalysis of studies
17. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data
18. The comparative efficacy of trazodone and imipramine in the treatment of depression
19. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis
20. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials
21. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
22. Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice
23. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose
24. Evidence of the dual mechanisms of action of venlafaxine
25. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials
26. Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders
27. Atypical depression, panic attacks and response to imipramine and phenelzine. A replication
28. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression
29. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
30. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression
31. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: A meta-analysis
32. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia
33. Response patterns of depressed outpatients with and without melancholia: A double-blind, placebo-controlled trial of fluoxetine versus placebo
34. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
35. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia
36. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
37. Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants
38. The pharmacological treatment of delusional depression
39. Psychotic (delusional) depression: A meta-analysis of physical treatments
40. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study
41. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression
42. Olanzapine response in psychotic depression
43. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder
44. Moclobemide and fluoxetine in treatment of seasonal affective disorder
45. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder
46. The efficacy of bupropion in winter depression: Results of an open trial
47. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up
48. Winter depression responds to an open trial of tranylcypromine
49. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety
50. A meta-analysis of the effects of venlafaxine on anxiety associated with depression
51. Therapeutic efficacy of antidepressants in agitated anxious depression: A meta-analysis of moclobemide studies
52. A meta-analysis of 8 randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety
53. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety
54. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice
55. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice
56. Managing the patient with depression and anxiety
57. A comparison of paroxetine, imipramine and placebo in depressed outpatients
58. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study
59. Double depression: A distinctive subtype of unipolar depression
60. Dysthymia: A biological perspective
61. Dysthymia and clinical practice
62. The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis
63. Treatment of dysthymia with sertraline: A double-blind, placebo-controlled trial in dysthymic patients without major depression
64. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia
65. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy
66. Venlafaxine in the treatment of dysthymia: An open-label study
67. Dysthymic disorder: Treatment with mirtazapine
68. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression
69. Response to treatment in minor and major depression: Results of a double-blind comparative study with paroxetine and maprotiline
70. Minor depressive disorder and subsyndromal depressive symptoms: Functional impairment and response to treatment
71. Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts
72. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
73. Tranylcypromine in recurrent brief depression: Two case reports
74. Mirtazapine in recurrent brief depression
75. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients
76. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine
77. Imipramine and sexual dysfunction during the long-term treatment of recurrent depression
78. Effects of antidepressant medication on sexual function: A controlled study
79. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice
80. Effects of SSRIs on sexual function: A critical review
81. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison ofbupropion sustained release and sertraline treatment
82. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients
83. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
84. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction
85. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction
86. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline
87. Sexual functioning in depressed outpatients taking mirtazapine
88. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
89. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients
90. Chronic imipramine treatment and weight gain
91. Comparative effects of 7 antidepressant regimes on appetite, weight and carbohydrate preference
92. Changes in weight during a 1-year trial of fluoxetine
93. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment
94. Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: A review of available evidence
95. Double-blind comparison of bupropion and fluoxetine in depressed outpatients
96. A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression
97. Safety and efficacy during long-term treatment with moclobemide
98. Multicenter double-blind study of moclobemide and maprotiline
99. Weight change during mirtazapine therapy
100. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
101. Discontinuation rates of SSRIs and tricyclic antidepressants: A meta-analysis and investigation of heterogeneity
102. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
103. Pharmacologic profile and efficacy of venlafaxine
104. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
105. Can the effects of antidepressants be observed in the first two weeks of treatment?
106. Timing of onset of antidepressant response with fluoxetine treatment
107. Fluoxetine versus moclobemide: Cross-comparison between the time courses of improvement
108. When at first you don't succeed: Sequential strategies for antidepressant nonresponders
109. Lithium augmentation in antidepressantresistant patients. A quantitative analysis
110. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
111. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression
112. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants
113. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis
114. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation
115. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine
116. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression
117. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
118. A novel augmentation strategy for treating resistant major depression
119. The increasing use of polypharmacotherapy for refractory mood disorders 22 years of study
120. The combined use of MAOIs and tricyclics
121. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study
122. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
123. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
124. Discontinuing antidepressant treatment in major depression
125. Optimal length of continuation therapy in depression a prospective assessment during long-term fluoxetine treatment
126. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression
127. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review
128. The SSRI discontinuation syndrome
129. The present status of electroconvulsive therapy: A systematic review
130. Medication resistance and clinical response to electroconvulsivc therapy
131. Resistance to antidepressant medications, and short-term clinical response to ECT
132. Relapse of depression after ECT: A review
133. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression
134. Clinical predictors of shortterm outcome in electroconvulsive therapy
135. Cost and benefit in the choice of ECT schedule. Twice versus 3 times weekly ECT
136. Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments
137. Repetitive transcranial magnetic stimulation: What are the next steps?
138. Electroconvulsive therapy requires higher dosage levels: Food and Drug Administration action is required
139. The ictal EEG as a marker of adequate stimulus intensity with unilateral ECT
140. Ambulatory electroconvulsive therapy: Report of a task force of the association for convulsive therapy
141. Use of ECT in California, revisited: 1984-1994
142. The effects of electroconvulsive therapy on memory of autobiographical and public events
143. A review of continuation and maintenance electroconvulsive therapy
144. Does ECT alter brain structure?
145. Discontinuation of antidepressant drugs during electroconvulsive therapy: A controlled study
146. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: A comparison with imipramine and placebo in medium-term continuation therapy
147. A controlled trial of timed bright light and negative air ionization for treatment of winter depression
148. Bright light treatment of winter depression: A placebo-controlled trial
149. Dose-response relationship of phototherapy for seasonal affective disorder: A meta-analysis
150. Light treatment for nonseasonal depression: Speed, efficacy, and combined treatment
151. St John's wort for depression
152. St John's wort for depression: A systematic review
153. Is sleep deprivation useful in the treatment of depression?
154. Sleep deprivation therapy
155. Sleep deprivation in depression: What do we know, where do we go?
156. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial
157. The effectiveness of exercise as an intervention in the management of depression: Systematic review and meta-regression analysis ofrandomised controlled trials
158. Effects of exercise training on older patients with major depression
159. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months
160. Psychosurgery
161. Psychosurgery: Stereotactic subcaudate tractomy. An indispensable treatment
162. Vagus nerve stimulation: A new tool for brain research and therapy
163. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study
164. Transcranial magnetic stimulation: Applications in neuropsychiatry